Literature DB >> 8580794

The association of inflammatory bowel disease and leukemia--coincidence or not?

O Caspi1, A Polliack, R Klar, D Ben-Yehuda.   

Abstract

Inflammatory bowel diseases, (IBD) including Crohn's disease and ulcerative colitis, are chronic systemic disorders associated with intestinal and other systemic features. Common hematological manifestations of IBD include: anemia, hypercoagulable state, leukocytosis and thrombocytosis. Recently it has been recognized that lymphoma and leukemia can also be associated with both Crohn's disease and ulcerative colitis. Careful review of the literature reveals more than 30 cases of leukemia reported in patients with IBD. Epidemiological data show that this association is statistically significant (relative risk of 5.3; p < 0.01; 95% confidence interval). This review attempts to characterize the clinical features of this association. The etiology of leukemia in these cases seems to be multifactorial and may involve: genetic susceptibility, environmental factors, immune abnormalities, prior exposure to diagnostic radiation and a variety of therapeutic modalities. No definitive time interval, specific pattern or correlation between the extent of bowel involvement and type of leukemia was found. Treatment of leukemia might affect the activity and severity of the inflammatory bowel disease, but there is very little data relating to this issue. There is some evidence suggesting that bone marrow transplantation performed for leukemia may induce remission of both diseases. Further investigation is still required in the future in order to establish a definite relationship between these two disorders.

Entities:  

Mesh:

Year:  1995        PMID: 8580794     DOI: 10.3109/10428199509056830

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.

Authors:  R J Farrell; Y Ang; P Kileen; D S O'Briain; D Kelleher; P W Keeling; D G Weir
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  Risk of haematopoietic cancer in patients with inflammatory bowel disease.

Authors:  J Askling; L Brandt; A Lapidus; P Karlén; M Björkholm; R Löfberg; A Ekbom
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

3.  Hematologic malignancies in the Japanese patients with inflammatory bowel disease.

Authors:  Norimasa Fukata; Kazuichi Okazaki; Mika Omiya; Mitsunobu Matsushita; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2013-08-19       Impact factor: 7.527

4.  Acute myeloblastic leukemia following prolonged treatment of Crohn's disease with 6-mercaptopurine.

Authors:  W D Heizer; J L Peterson
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

Review 5.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

6.  Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.

Authors:  María Gómez-García; Maria José Cabello-Tapia; Antonio Damián Sánchez-Capilla; Javier De Teresa-Galván; Eduardo Redondo-Cerezo
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

Review 7.  Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature.

Authors:  Pietro Crispino; Roberta Pica; Erika Angelucci; Adriana Consolazio; Margherita Rivera; Claudio Cassieri; Paolo Paoluzi
Journal:  Int J Colorectal Dis       Date:  2006-10-07       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.